Filing Flows › Denali Therapeutics (DNLI) › Q3 2026
Denali Therapeutics (DNLI) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Denali Therapeutics (DNLI) reported revenue of $17.8M for the third quarter 2026 (Q3 2026) and +393% from the quarter before. Operating margin was -713.0%, net earnings $70.1M (394.5% of revenue).
Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.8M | +393% | — |
| Operating profit | −$127M | — | — |
| Net earnings | $70.1M | — | — |
| Operating cash flow | −$117M | — | — |
What changed
Revenue was $17.8M in Q3 2026, up 393% from the previous quarter.
Operating costs exceeded revenue by $126.8M, an operating margin of -713.0%. Net earnings were $70.1M. The effective tax rate was 0.0%. Non-operating items added $196.9M, 281% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$117.4M. Non-cash charges added back $3.6M of depreciation and amortization and $22.9M of share-based compensation. Working capital and other items used $214.0M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$118.5M.
Questions
What was Denali Therapeutics' revenue in the third quarter 2026?
Denali Therapeutics (DNLI) reported revenue of $17.8M for the third quarter 2026 (Q3 2026) and +393% from the quarter before.
Was Denali Therapeutics profitable in the third quarter 2026?
Operating loss was $127M (-713.0% of revenue) and net earnings $70.1M.